Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer , Clinical Cancer Research : 2025
Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S. FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer , Communications medicine: 2025
Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B. Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy
, JACC. CardioOncology: 2025
Garrido-Castro AC, Kim SE, Desrosiers J, Nanda R, Carey LA, Clark AC, Sacks RL, O’Connor TP, Sinclair NF, Steve Lo KM, Thomas A, Wrabel E, O’Meara T, Lin NU, Burstein HJ, He M, Rimm DL, Mittendorf EA, Tayob N, Tolaney SM Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Texas Breast Cancer Symposium, San Antonio, TX : 2024
Puhalla SL, Tang G, Swain SM, Ganz PA, Lynn Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET) , San Antonio Breast Cancer Symposium, San Antonio, TX.: 2024
Garrido-Castro AC, Desrosiers JA, Nanda R, Abdou YG, Clark AS, Sacks RL, O'Connor TP, Sinclair NF, Lo S, Thomas A, Wrabel E, DiLullo MK, Patel A, Rahman T, O'Meara TA, Keenan T, Dillon, DA, Lin NU, Burstein HJ, Mittendorf EA, Junkins KE, Rahee HA Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Breast Cancer Symposium, San Antonio, TX: 2024
Linden HM, Ewen D, Mankoff D, Dehdashti F, Fowler AM, Clark AS, Specht JM, Peterson LM [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142 , San Antonio Texas Breast Cancer Symposium, San Antonio, TX: 2024
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky KM, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Torres ETR, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Yi Chen Y, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood M, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJ. Safety and efficacy of datopotamab-deruxtecan plus durvalumab in the I-SPY2.2 Sequential Multiple Assignment Randomized Trial , Nature Medicine: 2024
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien J, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Torres ETR, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van ‘t Veer LJ, Hylton NM, Esserman LJOuthaythip, Wen Li, Natsuko Onishi, Adam L. Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Brian Moore, W. Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula Pohlmann, Rebecca A. Shatsky, Angela DeMichele, Douglas Yee, Laura J. van ‘t Veer, Nola M. Hylton, Laura J. Esserman Datopotamab-deruxtecan in early-stage breast cancer: the phase 2 I-SPY2.2 sequential multiple assignment randomized trial , Nature Medicine: 2024
Swain S, Tang G, Puhalla SL, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009 , Journal of Clinical Oncology: 2024
